{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:14:35Z","timestamp":1790676875836,"version":"4.1.0"},"reference-count":147,"publisher":"Impact Journals, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2018,11,17]]},"DOI":"10.18632\/aging.101647","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T19:28:44Z","timestamp":1542482924000},"page":"3067-3078","source":"Crossref","is-referenced-by-count":51,"title":["Disease or not, aging is easily treatable"],"prefix":"10.18632","volume":"10","author":[{"given":"Mikhail V.","family":"Blagosklonny","sequence":"first","affiliation":[{"name":"Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,11,17]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fgene.2015.00205","article-title":"It is time to classify biological aging as a disease.","volume":"6","author":"Roy","year":"2015","journal-title":"Front Genet"},{"key":"2","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1038\/sj.embor.7400435","article-title":"Death as an unnatural process. Why is it wrong to seek a cure for aging?","volume":"6","author":"Caplan","year":"2005","journal-title":"EMBO Rep"},{"key":"3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fgene.2015.00212","article-title":"The aging-disease false dichotomy: understanding senescence as pathology.","volume":"6","author":"Gems","year":"2015","journal-title":"Front Genet"},{"key":"4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fgene.2015.00326","article-title":"Classifying aging as a disease in the context of ICD-11.","volume":"6","author":"Bhullar","year":"2015","journal-title":"Front Genet"},{"key":"5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.14336\/AD.2017.0130","article-title":"Recognizing Degenerative Aging as a Treatable Medical Condition: methodology and Policy.","volume":"8","author":"Stambler","year":"2017","journal-title":"Aging Dis"},{"key":"6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fgene.2015.00202","article-title":"Has aging ever been considered healthy?","volume":"6","author":"Stambler","year":"2015","journal-title":"Front Genet"},{"key":"7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fgene.2015.00171","article-title":"Should we treat aging as a disease? The consequences and dangers of miscategorisation.","volume":"6","author":"Faragher","year":"2015","journal-title":"Front Genet"},{"key":"8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0074-7742(08)60107-5","article-title":"Neuroendocrine-ontogenetic mechanism of aging: toward an integrated theory of aging.","volume":"2","author":"Golubev","year":"1986","journal-title":"Int Rev Neurobiol"},{"key":"9","unstructured":"Dilman VM. Four models of medicine. Medicina: Leningrad 1987."},{"key":"10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.4161\/cc.5.18.3288","article-title":"Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition.","volume":"5","author":"Blagosklonny","year":"2006","journal-title":"Cell Cycle"},{"key":"11","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.4161\/cc.9.16.13120","article-title":"Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program.","volume":"9","author":"Blagosklonny","year":"2010","journal-title":"Cell Cycle"},{"key":"12","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.4161\/cc.27188","article-title":"Aging is not programmed: genetic pseudo-program is a shadow of developmental growth.","volume":"1","author":"Blagosklonny","year":"2013","journal-title":"Cell Cycle"},{"key":"13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-physiol-030212-183712","article-title":"Genetics of longevity in model organisms: debates and paradigm shifts.","volume":"7","author":"Partridge","year":"2013","journal-title":"Annu Rev Physiol"},{"key":"14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1089\/ars.2012.4840","article-title":"Alternative Perspectives on Aging in Caenorhabditis elegans: Reactive Oxygen Species or Hyperfunction?","volume":"1","author":"de la Guardia","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41514-018-0025-3","article-title":"A parthenogenetic quasi-program causes teratoma-like tumors during aging in wild-type","volume":"4","author":"Gems","year":"2018","journal-title":"NPJ Aging Mech Dis"},{"key":"16","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.18632\/aging.101486","article-title":"Monsters in the uterus: teratoma-like tumors in senescentresult from a parthenogenetic quasi-program.","volume":"1","author":"Gems","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.18632\/aging.100034","article-title":"Validation of anti-aging drugs by treating age-related diseases.","volume":"1","author":"Blagosklonny","year":"2009","journal-title":"Aging (Albany NY)"},{"key":"18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.18632\/aging.100525","article-title":"Answering the ultimate question \u201cwhat is the proximal cause of aging?\u201d.","volume":"4","author":"Blagosklonny","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"19","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1038\/cddis.2013.506","article-title":"TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.","volume":"4","author":"Blagosklonny","year":"2013","journal-title":"Cell Death Dis"},{"key":"20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","article-title":"Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.","volume":"7","author":"Hildemann","year":"2015","journal-title":"Drugs"},{"key":"21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dc11-1299","article-title":"Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.","volume":"3","author":"Diabetes Prevention Program Research Group","year":"2012","journal-title":"Diabetes Care"},{"key":"22","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00125-017-4361-9","article-title":"Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program\/Diabetes Prevention Program Outcomes Study.","volume":"6","author":"Nathan","year":"2017","journal-title":"Diabetologia"},{"key":"23","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","article-title":"Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.","volume":"3","author":"Diabetes Prevention Program Research Group","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"24","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.2337\/db16-0240","article-title":"Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation.","volume":"6","author":"Holst","year":"2016","journal-title":"Diabetes"},{"key":"25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.2337\/dc09-0153","article-title":"Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report.","volume":"3","author":"Roth","year":"2009","journal-title":"Diabetes Care"},{"key":"26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/dmrr.2322","article-title":"Basal state hyperinsulinemia in healthy normoglycemic adults heralds dysglycemia after more than two decades of follow up.","volume":"2","author":"Roth","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"27","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.2337\/diabetes.53.suppl_3.S16","article-title":"Five stages of evolving beta-cell dysfunction during progression to diabetes.","volume":"5","author":"Bonner-Weir","year":"2004","journal-title":"Diabetes"},{"key":"28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00125-017-4468-z","article-title":"Glucose patterns during an oral glucose tolerance test and associations with future diabetes, cardiovascular disease and all-cause mortality rate.","volume":"6","author":"F\u00e6rch","year":"2018","journal-title":"Diabetologia"},{"key":"29","doi-asserted-by":"publisher","first-page":"E55","DOI":"10.1542\/peds.107.4.e55","article-title":"The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.","volume":"10","author":"Bursey","year":"2001","journal-title":"Pediatrics"},{"key":"30","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.","volume":"28","author":"Roccella","year":"2003","journal-title":"JAMA"},{"key":"31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ahj.2013.10.023","article-title":"Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis.","volume":"16","author":"Xu","year":"2014","journal-title":"Am Heart J"},{"key":"32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1891\/cmaj.5.2.107.66279","article-title":"Skin lesions in the elderly: precancer and cancer.","volume":"5","author":"Ollstein","year":"2004","journal-title":"Care Manag J"},{"key":"33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.18632\/aging.100479","article-title":"How to save Medicare: the anti-aging remedy.","volume":"4","author":"Blagosklonny","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.18632\/aging.100139","article-title":"Why human lifespan is rapidly increasing: solving \u201clongevity riddle\u201d with \u201crevealed-slow-aging\u201d hypothesis.","volume":"2","author":"Blagosklonny","year":"2010","journal-title":"Aging (Albany NY)"},{"key":"35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fmed.2018.00061","article-title":"The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates.","volume":"5","author":"Salvioli","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"36","doi-asserted-by":"publisher","first-page":"592","DOI":"10.18632\/aging.100591","article-title":"Rapamycin extends life- and health span because it slows aging.","volume":"5","author":"Blagosklonny","year":"2013","journal-title":"Aging (Albany NY)"},{"key":"37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/0300985815591082","article-title":"The Biology of Aging: Citizen Scientists and Their Pets as a Bridge Between Research on Model Organisms and Human Subjects.","volume":"5","author":"Kaeberlein","year":"2016","journal-title":"Vet Pathol"},{"key":"38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11357-018-0036-9","article-title":"How healthy is the healthspan concept?","volume":"4","author":"Kaeberlein","year":"2018","journal-title":"Geroscience"},{"key":"39","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00198-015-3325-5","article-title":"Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy.","volume":"2","author":"Lin","year":"2016","journal-title":"Osteoporos Int"},{"key":"40","doi-asserted-by":"publisher","first-page":"e1552","DOI":"10.1038\/cddis.2014.520","article-title":"Koschei the immortal and anti-aging drugs.","volume":"5","author":"Blagosklonny","year":"2014","journal-title":"Cell Death Dis"},{"key":"41","doi-asserted-by":"publisher","first-page":"35492","DOI":"10.18632\/oncotarget.18033","article-title":"From rapalogs to anti-aging formula.","volume":"8","author":"Blagosklonny","year":"2017","journal-title":"Oncotarget"},{"key":"42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.exger.2014.07.003","article-title":"What is an anti-aging treatment?","volume":"5","author":"Gems","year":"2014","journal-title":"Exp Gerontol"},{"key":"43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1126\/science.1173635","article-title":"Caloric restriction delays disease onset and mortality in rhesus monkeys.","volume":"32","author":"Weindruch","year":"2009","journal-title":"Science"},{"key":"44","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4161\/cc.9.4.10766","article-title":"Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans).","volume":"9","author":"Blagosklonny","year":"2010","journal-title":"Cell Cycle"},{"key":"45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.18632\/aging.100581","article-title":"Will calorie restriction work in humans?","volume":"5","author":"Fontana","year":"2013","journal-title":"Aging (Albany NY)"},{"key":"46","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.arr.2011.11.005","article-title":"Of mice and men: the benefits of caloric restriction, exercise, and mimetics.","volume":"1","author":"de Cabo","year":"2012","journal-title":"Ageing Res Rev"},{"key":"47","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1038\/ncomms4557","article-title":"Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys.","volume":"5","author":"Anderson","year":"2014","journal-title":"Nat Commun"},{"key":"48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1475-2891-10-107","article-title":"Impact of caloric and dietary restriction regimens on markers of health and longevity in humans and animals: a summary of available findings.","volume":"1","author":"Bloomer","year":"2011","journal-title":"Nutr J"},{"key":"49","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.2174\/13816128113196660699","article-title":"Calorie restriction and dietary restriction mimetics: a strategy for improving healthy aging and longevity.","volume":"2","author":"Chiarpotto","year":"2014","journal-title":"Curr Pharm Des"},{"key":"50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.arr.2014.11.005","article-title":"Calorie restriction mimetics: can you have your cake and eat it, too?","volume":"2","author":"Roth","year":"2015","journal-title":"Ageing Res Rev"},{"key":"51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrn.2017.156","article-title":"Intermittent metabolic switching, neuroplasticity and brain health.","volume":"1","author":"Cheng","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.arr.2016.10.005","article-title":"Impact of intermittent fasting on health and disease processes.","volume":"3","author":"Harvie","year":"2017","journal-title":"Ageing Res Rev"},{"key":"53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41467-017-00178-3","article-title":"Every-other-day feeding extends lifespan but fails to delay many symptoms of aging in mice.","volume":"8","author":"Lehmann","year":"2017","journal-title":"Nat Commun"},{"key":"54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.cmet.2017.08.005","article-title":"A Ketogenic Diet Extends Longevity and Healthspan in Adult Mice.","volume":"2","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"55","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.arr.2016.08.005","article-title":"Calorie restriction in humans: an update.","volume":"3","author":"Fontana","year":"2017","journal-title":"Ageing Res Rev"},{"key":"56","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.febslet.2011.03.015","article-title":"Calorie restriction and prevention of age-associated chronic disease.","volume":"58","author":"Fontana","year":"2011","journal-title":"FEBS Lett"},{"key":"57","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2008.05.036","article-title":"Ravussin E and team. ftPC. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals.","volume":"20","author":"Smith","year":"2009","journal-title":"Atherosclerosis"},{"key":"58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11357-009-9118-z","article-title":"Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production.","volume":"3","author":"Holloszy","year":"2010","journal-title":"Age (Dordr)"},{"key":"59","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.18632\/aging.101122","article-title":"Effects of dietary restriction on adipose mass and biomarkers of healthy aging in human.","volume":"8","author":"Aquilano","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"60","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jnutbio.2004.12.007","article-title":"Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems.","volume":"1","author":"Wan","year":"2005","journal-title":"J Nutr Biochem"},{"key":"61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1464-5491.2005.01760.x","article-title":"Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes--a randomized controlled trial.","volume":"2","author":"Gale","year":"2006","journal-title":"Diabet Med"},{"key":"62","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cmet.2016.06.001","article-title":"Fasting, Circadian Rhythms, and Time-Restricted Feeding in Healthy Lifespan.","volume":"2","author":"Panda","year":"2016","journal-title":"Cell Metab"},{"key":"63","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cmet.2017.07.001","article-title":"The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway.","volume":"2","author":"Sabatini","year":"2017","journal-title":"Cell Metab"},{"key":"64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/cr.2015.146","article-title":"Multiple amino acid sensing inputs to mTORC1.","volume":"2","author":"Hall","year":"2016","journal-title":"Cell Res"},{"key":"65","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.tibs.2013.01.004","article-title":"Nutrient signaling to mTOR and cell growth.","volume":"3","author":"Guan","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"66","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.","volume":"28","author":"Gray","year":"2009","journal-title":"J Biol Chem"},{"key":"67","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.4161\/cc.7.21.6919","article-title":"Growth stimulation leads to cellular senescence when the cell cycle is blocked.","volume":"7","author":"Blagosklonny","year":"2008","journal-title":"Cell Cycle"},{"key":"68","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.stem.2012.06.007","article-title":"mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis.","volume":"1","author":"Gutkind","year":"2012","journal-title":"Cell Stem Cell"},{"key":"69","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.4161\/cc.20683","article-title":"Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence.","volume":"1","author":"Sun","year":"2012","journal-title":"Cell Cycle"},{"key":"70","doi-asserted-by":"publisher","first-page":"8832","DOI":"10.1073\/pnas.1405723111","article-title":"Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.","volume":"11","author":"Blagosklonny","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"71","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.18632\/aging.101155","article-title":"Gerosuppression by pan-mTOR inhibitors.","volume":"8","author":"Blagosklonny","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"72","doi-asserted-by":"publisher","first-page":"231","DOI":"10.18632\/aging.100872","article-title":"Reversal of phenotypes of cellular senescence by pan-mTOR inhibition.","volume":"8","author":"Cox","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"73","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/acel.12587","article-title":"Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.","volume":"1","author":"Perez","year":"2017","journal-title":"Aging Cell"},{"key":"74","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ncb3195","article-title":"MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.","volume":"1","author":"Li","year":"2015","journal-title":"Nat Cell Biol"},{"key":"75","doi-asserted-by":"publisher","first-page":"15802","DOI":"10.18632\/oncotarget.4602","article-title":"p53 and rapamycin are additive.","volume":"6","author":"Hasty","year":"2015","journal-title":"Oncotarget"},{"key":"76","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.4161\/cc.9.10.11872","article-title":"Rapamycin and quasi-programmed aging: four years later.","volume":"9","author":"Blagosklonny","year":"2010","journal-title":"Cell Cycle"},{"key":"77","doi-asserted-by":"publisher","first-page":"ra75","DOI":"10.1126\/scisignal.2000559","article-title":"mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells.","volume":"2","author":"Zheng","year":"2009","journal-title":"Sci Signal"},{"key":"78","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","article-title":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.","volume":"46","author":"Miller","year":"2009","journal-title":"Nature"},{"key":"79","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.2353\/ajpath.2010.091050","article-title":"Rapamycin extends maximal lifespan in cancer-prone mice.","volume":"17","author":"Blagosklonny","year":"2010","journal-title":"Am J Pathol"},{"key":"80","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.4161\/cc.10.24.18486","article-title":"Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice.","volume":"1","author":"Blagosklonny","year":"2011","journal-title":"Cell Cycle"},{"key":"81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/gerona\/glq178","article-title":"Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice.","volume":"6","author":"Sharp","year":"2011","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"82","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1474-9726.2012.00832.x","article-title":"Rapamycin slows aging in mice.","volume":"1","author":"Miller","year":"2012","journal-title":"Aging Cell"},{"key":"83","doi-asserted-by":"publisher","first-page":"715","DOI":"10.18632\/aging.100496","article-title":"New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-\/- mice by delaying carcinogenesis.","volume":"4","author":"Antoch","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"84","doi-asserted-by":"publisher","first-page":"709","DOI":"10.18632\/aging.100498","article-title":"Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+\/- mice.","volume":"4","author":"Gudkov","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"85","doi-asserted-by":"publisher","first-page":"100","DOI":"10.18632\/aging.100533","article-title":"Rapamycin extends life span of Rb1+\/- mice by inhibiting neuroendocrine tumors.","volume":"5","author":"Sharp","year":"2013","journal-title":"Aging (Albany NY)"},{"key":"86","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1172\/JCI67674","article-title":"Rapamycin extends murine lifespan but has limited effects on aging.","volume":"12","author":"Holtmeier","year":"2013","journal-title":"J Clin Invest"},{"key":"87","doi-asserted-by":"publisher","first-page":"e83988","DOI":"10.1371\/journal.pone.0083988","article-title":"Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome.","volume":"9","author":"Richardson","year":"2014","journal-title":"PLoS One"},{"key":"88","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/acel.12211","article-title":"Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet.","volume":"1","author":"Blagosklonny","year":"2014","journal-title":"Aging Cell"},{"key":"89","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/acel.12194","article-title":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction.","volume":"1","author":"Sharp","year":"2014","journal-title":"Aging Cell"},{"key":"90","doi-asserted-by":"publisher","first-page":"586","DOI":"10.4161\/cbt.28164","article-title":"Lifespan extension and cancer prevention in HER-2\/neu transgenic mice treated with low intermittent doses of rapamycin.","volume":"1","author":"Blagosklonny","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"91","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1093\/hmg\/ddx341","article-title":"Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome.","volume":"2","author":"Schon","year":"2017","journal-title":"Hum Mol Genet"},{"key":"92","doi-asserted-by":"publisher","first-page":"48","DOI":"10.18632\/aging.100633","article-title":"BMAL1-dependent regulation of the mTOR signaling pathway delays aging.","volume":"6","author":"Kondratov","year":"2014","journal-title":"Aging (Albany NY)"},{"key":"93","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1126\/science.1244360","article-title":"mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.","volume":"34","author":"Ramos","year":"2013","journal-title":"Science"},{"key":"94","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fgene.2015.00247","article-title":"Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice.","volume":"6","author":"Sangesland","year":"2015","journal-title":"Front Genet"},{"key":"95","doi-asserted-by":"publisher","first-page":"5","DOI":"10.7554\/eLife.16351","article-title":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice.","volume":"5","author":"Beyer","year":"2016","journal-title":"eLife"},{"key":"96","doi-asserted-by":"publisher","first-page":"44876","DOI":"10.18632\/oncotarget.10381","article-title":"Rapamycin in aging and disease: maximizing efficacy while minimizing side effects.","volume":"7","author":"Kaeberlein","year":"2016","journal-title":"Oncotarget"},{"key":"97","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/acel.12109","article-title":"Late-life rapamycin treatment reverses age-related heart dysfunction.","volume":"1","author":"Melov","year":"2013","journal-title":"Aging Cell"},{"key":"98","doi-asserted-by":"publisher","first-page":"539","DOI":"10.18632\/aging.100576","article-title":"Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance.","volume":"5","author":"Baur","year":"2013","journal-title":"Aging (Albany NY)"},{"key":"99","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/acel.12203","article-title":"Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart.","volume":"1","author":"Rabinovitch","year":"2014","journal-title":"Aging Cell"},{"key":"100","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neuropharm.2017.01.039","article-title":"Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses.","volume":"11","author":"Chiarugi","year":"2017","journal-title":"Neuropharmacology"},{"key":"101","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/jcmm.13091","article-title":"Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1\/cyclin axis.","volume":"2","author":"Liang","year":"2017","journal-title":"J Cell Mol Med"},{"key":"102","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.4161\/15384101.2014.970491","article-title":"Comparison of rapamycin schedules in mice on high-fat diet.","volume":"1","author":"Blagosklonny","year":"2014","journal-title":"Cell Cycle"},{"key":"103","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.4161\/15384101.2014.949150","article-title":"Fasting levels of hepatic p-S6 are increased in old mice.","volume":"1","author":"Blagosklonny","year":"2014","journal-title":"Cell Cycle"},{"key":"104","doi-asserted-by":"publisher","first-page":"eaaq1564","DOI":"10.1126\/scitranslmed.aaq1564","article-title":"TORC1 inhibition enhances immune function and reduces infections in the elderly.","volume":"1","author":"Klickstein","year":"2018","journal-title":"Sci Transl Med"},{"key":"105","doi-asserted-by":"publisher","first-page":"e93691","DOI":"10.1371\/journal.pone.0093691","article-title":"Single rapamycin administration induces prolonged downward shift in defended body weight in rats.","volume":"9","author":"Blundell","year":"2014","journal-title":"PLoS One"},{"key":"106","doi-asserted-by":"publisher","first-page":"964","DOI":"10.18632\/aging.100843","article-title":"Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus).","volume":"7","author":"Tardif","year":"2015","journal-title":"Aging (Albany NY)"},{"key":"107","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11357-017-9972-z","article-title":"A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.","volume":"3","author":"Kaeberlein","year":"2017","journal-title":"Geroscience"},{"key":"108","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00228-012-1407-2","article-title":"The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers.","volume":"6","author":"Patat","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"109","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/00007691-200010000-00006","article-title":"Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers.","volume":"2","author":"Groth","year":"2000","journal-title":"Ther Drug Monit"},{"key":"110","doi-asserted-by":"publisher","first-page":"268ra179","DOI":"10.1126\/scitranslmed.3009892","article-title":"mTOR inhibition improves immune function in the elderly.","volume":"6","author":"Klickstein","year":"2014","journal-title":"Sci Transl Med"},{"key":"111","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2.","volume":"2","author":"Neven","year":"2014","journal-title":"Ann Oncol"},{"key":"112","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exger.2017.12.026","article-title":"A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.","volume":"10","author":"Kellogg","year":"2018","journal-title":"Exp Gerontol"},{"key":"113","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jgg.2014.06.009","article-title":"Rapamycin and ageing: when, for how long, and how much?","volume":"4","author":"Kaeberlein","year":"2014","journal-title":"J Genet Genomics"},{"key":"114","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ajog.2017.06.003","article-title":"Metformin, the aspirin of the 21st century: its\u00a0role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and\u00a0the promotion of longevity.","volume":"21","author":"Grossman","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"115","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1161\/CIRCULATIONAHA.116.025483","article-title":"Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium.","volume":"13","author":"Temprosa","year":"2017","journal-title":"Circulation"},{"key":"116","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating metformin for cancer prevention and treatment: the end of the beginning.","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov"},{"key":"117","doi-asserted-by":"publisher","first-page":"39398","DOI":"10.18632\/oncotarget.6347","article-title":"Metformin for cancer and aging prevention: is it a time to make the long story short?","volume":"6","author":"Anisimov","year":"2015","journal-title":"Oncotarget"},{"key":"118","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing metformin for the prevention of cancer and cancer recurrence.","volume":"6","author":"Ford","year":"2017","journal-title":"Diabetologia"},{"key":"119","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/ijc.31016","article-title":"Risk of Cause-Specific Death in Individuals with Cancer-Modifying Role Diabetes, Statins and Metformin.","volume":"14","author":"Auvinen","year":"2017","journal-title":"Int J Cancer"},{"key":"120","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/MAJ.0b013e31816250e6","article-title":"Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.","volume":"33","author":"Wall","year":"2008","journal-title":"Am J Med Sci"},{"key":"121","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.4161\/cc.7.17.6625","article-title":"Metformin slows down aging and extends life span of female SHR mice.","volume":"7","author":"Semenchenko","year":"2008","journal-title":"Cell Cycle"},{"key":"122","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18632\/aging.100273","article-title":"If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.","volume":"3","author":"Poroshina","year":"2011","journal-title":"Aging (Albany NY)"},{"key":"123","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/ncomms3192","article-title":"Metformin improves healthspan and lifespan in mice.","volume":"4","author":"Zhang","year":"2013","journal-title":"Nat Commun"},{"key":"124","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cell.2013.02.035","article-title":"Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism.","volume":"15","author":"Gems","year":"2013","journal-title":"Cell"},{"key":"125","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.cell.2016.11.055","article-title":"An Ancient, Unified Mechanism for Metformin Growth Inhibition in C.\u00a0elegans and Cancer.","volume":"16","author":"Soukas","year":"2016","journal-title":"Cell"},{"key":"126","doi-asserted-by":"publisher","first-page":"6","DOI":"10.7554\/eLife.31268","article-title":"Metformin extendslifespan through lysosomal pathway.","volume":"6","author":"Liu","year":"2017","journal-title":"eLife"},{"key":"127","doi-asserted-by":"publisher","first-page":"E2501","DOI":"10.1073\/pnas.1321776111","article-title":"Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2.","volume":"11","author":"Temmerman","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"128","doi-asserted-by":"publisher","first-page":"760","DOI":"10.18632\/aging.100230","article-title":"Metformin for aging and cancer prevention.","volume":"2","author":"Anisimov","year":"2010","journal-title":"Aging (Albany NY)"},{"key":"129","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.4161\/cc.26928","article-title":"Metformin: do we finally have an anti-aging drug?","volume":"1","author":"Anisimov","year":"2013","journal-title":"Cell Cycle"},{"key":"130","doi-asserted-by":"publisher","first-page":"9017","DOI":"10.18632\/oncotarget.14794","article-title":"Metformin: a metabolic modulator.","volume":"8","author":"Kroemer","year":"2017","journal-title":"Oncotarget"},{"key":"131","doi-asserted-by":"publisher","first-page":"386","DOI":"10.18632\/aging.101401","article-title":"Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice.","volume":"1","author":"Salmon","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"132","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.bcp.2009.06.018","article-title":"Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats.","volume":"7","author":"Pesquero","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"133","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11357-016-9948-4","article-title":"Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice.","volume":"3","author":"Flegal","year":"2016","journal-title":"Age (Dordr)"},{"key":"134","doi-asserted-by":"publisher","first-page":"H1351","DOI":"10.1152\/ajpheart.00393.2007","article-title":"Protective effect of long-term angiotensin II inhibition.","volume":"29","author":"Inserra","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"135","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.","volume":"31","author":"Mangione","year":"2016","journal-title":"JAMA"},{"key":"136","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s11357-012-9498-3","article-title":"\u03b21-Adrenergic receptor blockade extends the life span of Drosophila and long-lived mice.","volume":"3","author":"Lublin","year":"2013","journal-title":"Age (Dordr)"},{"key":"137","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ahj.2013.04.011","article-title":"The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.","volume":"16","author":"Visseren","year":"2013","journal-title":"Am Heart J"},{"key":"138","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1177\/2047487314530382","article-title":"A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.","volume":"2","author":"Bompoint","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"139","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/1747493018761190","article-title":"Cut stroke in half: polypill for primary prevention in stroke.","volume":"1","author":"Wiseman","year":"2018","journal-title":"Int J Stroke"},{"key":"140","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrclinonc.2013.169","article-title":"Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates.","volume":"1","author":"Rennert","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"141","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/bcr3336","article-title":"Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.","volume":"1","author":"Chen","year":"2012","journal-title":"Breast Cancer Res"},{"key":"142","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1097\/MCG.0b013e3181ea1044","article-title":"Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps.","volume":"4","author":"Siddiqui","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"143","doi-asserted-by":"publisher","first-page":"628","DOI":"10.18632\/oncotarget.101009","article-title":"Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.","volume":"1","author":"Entschladen","year":"2010","journal-title":"Oncotarget"},{"key":"144","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","article-title":"Beta blockers and breast cancer mortality: a population- based study.","volume":"2","author":"Visvanathan","year":"2011","journal-title":"J Clin Oncol"},{"key":"145","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11912-013-0351-3","article-title":"Role of aspirin in cancer prevention.","volume":"1","author":"Cuzick","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"146","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.4161\/cbt.7.10.6663","article-title":"Prevention of cancer by inhibiting aging.","volume":"7","author":"Blagosklonny","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"147","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ajpath.2012.06.024","article-title":"Prospective treatment of age-related diseases by slowing down aging.","volume":"18","author":"Blagosklonny","year":"2012","journal-title":"Am J Pathol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.101647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T18:17:24Z","timestamp":1599070644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.101647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,17]]},"references-count":147,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,30]]}},"alternative-id":["101647","30448823"],"URL":"https:\/\/doi.org\/10.18632\/aging.101647","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,17]]}}}